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1. Introduction
   The current outbreak started officially on March 23, 2014, when 
the World Health Organization (WHO) was notified of an outbreak 
of Ebola virus disease (EVD) in Guinea, even if the epidemics 
started on October 2013[1]. Almost five months later, on August 8, 
the WHO declared the epidemic reached the level of a public health 
emergency of international concern[2].
   But why are we so interested in the evolving of this outbreak? The 
forecast of the WHO Ebola response team says that at the beginning 
of November 2014, and assuming no change in the control measures 
for this epidemic, the cumulative reported numbers of confirmed 
and probable cases will exceed 20 000 (5 740 in Guinea, 9 890 in 
Liberia, and 5 000 in Sierra Leone)[3].
   By September 14, 2014, a total of 4 507 probable and confirmed 
cases, including 2 296 deaths from EVD (Zaire species) had been 
reported from five countries in West Africa-Guinea, Liberia, Nigeria, 
Senegal, and Sierra Leone.
   The WHO recently underlined that “Ebola virus disease currently 
has no vaccines or medicines approved by national regulatory 
authorities for use in humans save for the purpose of compassionate 
care”[4].
   Lamontagne et al. have argued that the role of public health in 
stopping Ebola is and will be important also in the next future, 
through the characterization of the outbreak epidemiology, of 
contact tracing, social mobilization, and public education[5]. It is 
well known that public health intervention are capable of saving 
many more lives than can be saved by individual patient care. 
However, the prevention and the treatment of EVD are essential 
issues to take into account in the control of the outbreak, and the 
objective of this paper is to review the current scientific literature on 
the treatment and prevention of EVD.
   Essentially, this paper will highlight the ways researchers are 
following for helping people just exposed to Ebola virus survive 
(treatment) and to prevent the disease when given at various times 
after exposure (vaccine).
2. Treatment 
   Current treatment for EVD consists of supportive care. As the virus 
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reproduces and spreads in the body, it interferes with blood clotting 
and disrupts electrolyte balance. As a result, severely ill patients are 
frequently dehydrated and need intravenous fluids or oral rehydration 
with solutions that contain electrolytes. Such interventions can help 
sustain some patients and allow them to recover, but in many cases, 
patients progress toward multiorgan failure, shock, and death.
   Recombinant anti-Ebola monoclonal antibodies and small 
interfering RNAs that block the expression of essential viral proteins, 
are the most promising way in stopping the disease when it has 
already reached the humans.
   The research on finding effective drug for this diseases suffered 
from the fact that EVD until now should be considered a rare disease. 
Theoretically, the most effective way in stopping the disease when 
it has been already acquired by humans is the administration of 
specific antibodies. In this field, Mapp Biopharmaceutical, a small 
biotechnology enterprise, conducted preclinical testing of ZMapp, 
a passive immunotherapy that combines 3 humanized monoclonal 
antibodies produced in genetically modified Nicotinia plants.
   A trial of this product conducted by Qiu et al. administered up to 
5 d after experimental administration of macaque monkeys with a 
virulent Ebola virus strain, indicates a 100% efficacy in preventing 
lethal disease[6].
   On the basis of these results, two different things happened in 
recent days: first of all, 6 health workers and a priest received doses 
of ZMapp, and secondly, the US government signed a multimillion 
dollar contract for several million dollar with the maker of the 
experimental Ebola drug ZMapp with the aim of accelerating the 
drug’s development[7].
   At this point in time, the scarce availability of the product needs 
to be taken into account for tackling efficaciously the disease at the 
epidemic level in Africa.
   On the other hand, we have to consider that new drugs are under 
development[8]. One of this novel drugs is TKM-Ebola[9]. This 
drug is now under Phase I clinical trial conducted by Tekmira, a 
pharmaceutical corporation. The randomized, single-blind, placebo-
controlled study involves single ascending doses and multiple 
ascending doses of TKM-Ebola, and aims to assess safety, tolerability 
and pharmacokinetics of administering TKM-Ebola to healthy adult 
volunteers without administering any steroid pre-medications[10].
   Other experimental therapies include BCX4430, a synthetic 
adenosine analogue with high in vitro and in vivo activity against 
filoviruses and other RNA viruses. This drug inhibits viral 
RNA polymerase activity and protects cynomolgus macaques 
from Marburg virus infection if inoculated as late as 48 h after 
infection[11]. However, we have to report that no data safety in 
humans are still available from clinical trials.
   Other well known drugs, such as chloroquine and imatinib, have 
been tested in prelimnary in vitro studies, showing activity against 
Ebola virus and in rodent models[12].
   Finally, Tan et al. emphasized the potential utility for the use of 
melatonin in the treatment of individuals who were affected by 
EVD[13]. Since the pathological changes associated with an Ebola 
infection include endothelial disruption, disseminated intravascular 
coagulation and multiple organ hemorrhage, they suggest that 
melatonin could be used, based on the fact it targets these alterations. 
However, this use of melatonin has not been tested for safety and 
efficacy, even if this drug is characterized to have a high safety 
profile, to be readily-available and be orally-self administered.
   When thousands of people are confronted with a life-threatening 
disease, and no specific therapies or preventive measures exist, it 
can be ethically acceptable to assume greater risks and offer patients 
unproven interventions[14].
3. Prevention
   There is evidence that several non-human species, including 
primates and fruit bats, can be infected with the Ebola virus. 
Moreover, wild animals are the likely source of infection for 
outbreaks in humans[15]. However, the mortality rates after Ebola 
infection is high in the primates (25% in a chimpanzee community 
in the 1990’s in Cote d’Ivoire)[16] and it is difficult to argue that these 
animals could constitute the reservoir of the infection in wild life. 
On the other hand, bats are considered the better candidate for this 
role. Fruit bats could act as source of infection since, even infected 
with Ebola, they do not became ill, probably because they develop 
protective antibodies against the Ebola virus[17,18]. Another point is 
concerning the transmission of the infection from bats to humans. 
How could this happen? Leroy et al. argued that the start of at least 
one Ebola outbreak in humans has been linked to people consuming 
bat meat[19].
   If so, a better knowledge of this mean of transmission among the 
population and mapping Ebola in wild animals[20] could be useful 
for controlling the spread of the infection.
   As far as concerns the availability of a vaccine, at the end of 
September 2014, WHO consultation on Ebola vaccines in Geneva has 
stated that two candidate vaccines have clinical-grade vials available 
for phase 1 pre-licensure clinical trials[21], and demonstrated to have 
a 100% efficacy in studies on non human primates[22].
   The first candidate, cAd3-ZEBOV, has been conceived by Nicosia 
and Cortese and developed by GlaxoSmithKline in collaboration 
with the US National Institute of Allergy and Infectious Diseases. 
This vaccine uses a chimpanzee-derived adenovirus vector with an 
Ebola virus gene inserted[23].
   The second candidate, rVSV-ZEBOV, has been developed by the 
Public Health Agency of Canada in Winnipeg. rVSV-ZEBOV uses an 
attenuated or weakened vesicular stomatitis virus, a pathogen found 
in livestock; one of its genes has been replaced by an Ebola virus 
gene[24].
   As discussed in the WHO meeting in Geneva[21], phase 1 trials 
should be expedited and their results shared broadly in order 
to facilitate rapid progression to phase 2. There is a substantial 
agreement on the fact that if the results of phase 1 will be favorable, 
phase 2a studies should be conducted in Africa but outside the 
current Ebola outbreak zone and should proceed in parallel with 
phase 2b studies to carry out in exposed populations to the current 
outbreak.
   A final consideration is due. We agree with the Nature editorial 
that it’s time to act[25]. We are pretty sure that well-informed 
communities can reduce the main ways of spread the infection, by 
avoiding unprotected home-based care of people who are infected 
and also by completely modifying traditional burial practices that are 
way of diffusion of the contagion.
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